

This document certifies that the manuscript

**Cisplatin, Docetaxel, and Cetuximab (TPEX) as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer: A Multicenter Real-World Study**

prepared by the authors

Agustín Falco, MD1; Mariano Leiva, MD1; Albano Blanco, MD1; Guido Cefarelli, MD1; Andrés Rodríguez, MD1; Juan Melo, MD2; Federico Cayol, MD2; Manglio Rizzo, MD, PhD3; Alejandro Sola, MD4; Hernán Rodríguez Montani, MD5,6; Matías Chacón, MD1; Diego Enrico, MD1\*; and Federico Waisberg, MD1\*.

was edited for proper English language, grammar, punctuation, spelling, and overall style by one or more of the highly qualified native English speaking editors at SNAS.

This certificate was issued on **June 14, 2021** and may be verified on the [SNAS website](#) using the verification code **4E76-8E4A-31EB-BD1D-9FA0**.

Neither the research content nor the authors' intentions were altered in any way during the editing process. Documents receiving this certification should be English-ready for publication; however, the author has the ability to accept or reject our suggestions and changes. To verify the final

SNAS edited version, please visit our verification page at [secure.authorservices.springernature.com/certificate/verify](https://secure.authorservices.springernature.com/certificate/verify).

If you have any questions or concerns about this edited document, please contact SNAS at [support@as.springernature.com](mailto:support@as.springernature.com).